Factors Associated with Doses of Mood Stabilizers in Real-world Outpatients with Bipolar Disorder

Norio Yasui-Furukori1,2, Naoto Adachi3, Yukihisa Kubota3, Takaharu Azekawa3, Eiichiro Goto3, Koji Edagawa3, Eiichi Katsumoto3, Seiji Hongo3, Hitoshi Ueda3, Kazuhira Miki3, Masaki Kato2,4, Reiji Yoshimura2,5, Atsuo Nakagawa2,6, Toshiaki Kikuchi2,6, Takashi Tsuboi2,7, Koichiro Watanabe2,7, Kazutaka Shimoda1

1Department of Psychiatry, Dokkyo Medical University, School of Medicine, Tochigi, 2The Japanese Society of Clinical Neuropsychopharmacology, 3The Japanese Association of Neuro-Psychiatric Clinics, Tokyo, 4Department of Neuropsychiatry, Kansai Medical University, Hirakata, 5Department of Psychiatry, University of Occupational and Environmental Health, Kitakyushu, 6Department of Neuropsychiatry, Keio University School of Medicine, Minato, 7Department of Neuropsychiatry, Kyorin University School of Medicine, Mitaka, Japan

Objective: Several evidence-based practice guidelines have been developed to better treat bipolar disorder. However, the articles cited in these guidelines were based on clinical or basic studies with specific conditional settings and were not sufficiently based on real-world clinical practice. In particular, there was little information on the doses of mood stabilizers.

Methods: The MUlticenter treatment SUrvey on BIpolar disorder in Japanese psychiatric clinics (MUSUBI) is a study conducted to accumulate evidence on the real-world practical treatment of bipolar disorder. The questionnaire included patient characteristics such as comorbidities, mental status, treatment period, Global Assessment of Functioning (GAF) score, and details of pharmacological treatment.

Results: Most patients received mood stabilizers such as lithium (n = 1,317), valproic acid (n = 808), carbamazepine (n = 136), and lamotrigine (n = 665). The dose of lithium was correlated with age, body weight, number of episodes, depression and GAF. The dose of valproic acid was correlated with body weight, number of episodes, presence of a rapid cycle and GAF. The dose of carbamazepine was correlated with age, mania, and the presence of a rapid cycle. The dose of lamotrigine was correlated with the number of episodes, depression, mania, psychotic features, and the presence of a rapid cycle. Doses of coadministered mood stabilizers were significantly correlated, except for the combination of valproic acid and lamotrigine.

Conclusion: The dose of mood stabilizers was selectively administered based on several factors, such as age, body composition, current mood status and functioning. Further prospective studies are required to confirm these findings.

KEY WORDS: Bipolar disorder; Mood stabilizers; Nationwide study; Real world; Dose.

INTRODUCTION

For the treatment of bipolar disorders, mood stabilizers are still categorized as a first-line treatment for manic and depressive episodes and the maintenance phase [1]. A previous network meta-analysis demonstrated that lithium, valproic acid (VPA), and lamotrigine (LTG) but not carbamazepine (CBZ) were more effective than placebo [2]. However, the findings of this study are difficult to apply in the context of real-world clinical practice. The International College of Neuropsychopharmacology Treatment Guidelines for Bipolar Disorder (CINP-BD) has recently recommended that monotherapy with aripiprazole, asenapine, cariprazine, paliperidone, quetiapine, risperidone or VPA is a first-line treatment for manic patients [3]. Monotherapy with quetiapine, lurasidone or olanzapine-flutamide combination is the first-line treatment for depressive patients, and monotherapy with lithium, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone or risperidone long-acting injectables was a

and that the tolerability of CBZ was inferior to that of placebo [2]. However, the findings of this study are difficult to apply in the context of real-world clinical practice. The International College of Neuropsychopharmacology Treatment Guidelines for Bipolar Disorder (CINP-BD) has recently recommended that monotherapy with aripiprazole, asenapine, cariprazine, paliperidone, quetiapine, risperidone or VPA is a first-line treatment for manic patients [3]. Monotherapy with quetiapine, lurasidone or olanzapine-flutamide combination is the first-line treatment for depressive patients, and monotherapy with lithium, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone or risperidone long-acting injectables was a
first-line treatment in maintenance therapy [3]. In addition, the Canadian Network for Mood and Anxiety Treatments (CANMAT 2018) has recently suggested that monotherapy with lithium or divalproex is recommended as a first-line treatment for acute mania [4]. Quetiapine and lurasidone monotherapy are recommended as first-line options for bipolar depression [4]. Lithium, LTG and divalproex are recommended options for the maintenance phase [4]. The Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP) [5], which was the most recent guideline for bipolar disorder, suggested that the preferred first-step strategies were VPA, lithium, olanzapine and quetiapine for acute mania; lithium, VPA, LTG, aripiprazole, and quetiapine for depression; and a combination of mood stabilizers and atypical antipsychotics for maintenance. However, there is little information on adequate doses of mood stabilizers for the treatment of bipolar disorders, although the therapeutic reference ranges are 0.5−1.2 mmol/L for lithium, 50−100 μg/ml for VPA, 4−10 μg/ml for CBZ and 1−6 μg/ml for LTG [6].

A previous study suggested that the doses of mood stabilizers tend to be adjusted based on clinical response, including adverse effects. There were negative associations between serum levels of VPA and short-term delayed recall and working memory. A positive association was suggested between the serum level of lithium and working memory [7]. Although therapeutic drug monitoring (TDM) applications for neuropsychiatric agents aim to assist clinicians in enhancing the safety and efficacy of treatment, most patients do not apply for TDM in the treatment of bipolar disorders in Japan [8]. Most side effects can be transient or dose related and can be managed by optimizing drug doses to the lowest effective dose [9]. In addition, the optimal dose of mood stabilizers might have been influenced by other clinical conditions, such as age, sex, psychiatric features, comorbid symptoms and other mood stabilizers.

More than 90% of all patients with mood disorders in Japan are outpatients, 30% of whom are treated at the clinics of Japanese Association of Neuro-Psychiatric Clinics members [10]. Therefore, we aimed to search for potential factors associated with the optimal doses of mood stabilizers in stable outpatients in good practical situations.

METHODS

Study Design and Subjects

Joint research (the MUlticenter treatment SUrvey on Bipolar disorder in Japanese psychiatric clinics, MUSUBI) was conducted between the Japanese Association of Neuro-Psychiatric Clinics and the Japanese Society of Clinical Neuropsychopharmacology to accumulate evidence on the real-world practical treatment of bipolar disorder in Japan. The method and design of MUSUBI has been described previously [11]. The MUSUBI is a cross-sectional study in which a questionnaire was administered at 176 outpatient clinics belonging to the Japanese Association of Neuro-Psychiatric Clinics from September to October 2016 [11]. Patients diagnosed with bipolar disorder based on the International Classification of Diseases, 10th edition criteria (World Health Organization, 1992) and treated at these clinics were included in this study.

This study protocol was reviewed and approved by the institutional review board of the ethics committee of the Japanese Association of Neuro-Psychiatric Clinics (ID. 20160822). This study was conducted in accordance with the Declaration of Helsinki and the Japanese Ethical Guidelines for Medical and Health Research Involving Human Subjects. Prior to the initiation of the study, the study protocol was reviewed and approved by the institutional review board of the ethics committee of the Japanese Association of Neuro-Psychiatric Clinics. Since this was a retrospective medical record survey, the informed consent requirement was exempted, but we instead released information on this research so that patients were free to opt out [11].

Study Procedures

Clinical psychiatrists were asked to complete a questionnaire about patients with bipolar disorder by performing a retrospective medical record survey. The questionnaire included patient characteristics (age, sex, height, weight, academic background, mental status), treatment period, Global Assessment of Functioning (GAF) score, and details of pharmacological treatment. We mailed 20 copies of this questionnaire to each outpatient clinic and analyzed the responses. This study focused on antidepressant prescriptions for bipolar disorder patients and their profiles.
Table 1. Characteristics of subjects receiving mood stabilizers

| Variable                      | Lithium (n = 1,317) | Valproic acid (n = 808) | Carbamazepine (n = 136) | Lamotrigine (n = 665) |
|-------------------------------|---------------------|------------------------|-------------------------|-----------------------|
| Age (yr)                      | 51.7 ± 13.7         | 50.8 ± 13.2            | 52.6 ± 12.5             | 46.9 ± 12.5           |
| Sex (male = 1, female = 2)    | 1.5 ± 0.50          | 1.53 ± 0.50            | 1.5 ± 0.50              | 1.54 ± 0.499          |
| Height (cm)                   | 163 ± 8.7           | 162 ± 8.4              | 162 ± 8.8               | 163 ± 8.4             |
| Weight (kg)                   | 63 ± 12.6           | 64 ± 13.2              | 63 ± 13.5               | 62 ± 12.3             |
| Educationa                   | 2.9 ± 1.1           | 2.7 ± 1.1              | 2.6 ± 1.1               | 3.0 ± 1.1             |
| Current status of depressionb | 0.57 ± 0.70         | 0.64 ± 0.72            | 0.66 ± 0.70             | 0.77 ± 0.77           |
| Current status of maniaa      | 0.20 ± 0.46         | 0.25 ± 0.50            | 0.33 ± 0.58             | 0.18 ± 0.43           |
| Current status of psychotic featureb | 0.06 ± 0.26    | 0.07 ± 0.28            | 0.16 ± 0.39             | 0.09 ± 0.30           |
| Current status of suicidal ideationb | 0.09 ± 0.31   | 0.13 ± 0.38            | 0.17 ± 0.40             | 0.16 ± 0.41           |
| Current status of substance useb | 0.05 ± 0.23   | 0.06 ± 0.27            | 0.10 ± 0.32             | 0.06 ± 0.26           |
| Current status of rapid cyclerb | 0.12 ± 0.33    | 0.13 ± 0.34            | 0.20 ± 0.40             | 0.14 ± 0.34           |
| Global assessment of functioningc | 0.88 ± 0.78 | 0.97 ± 0.78            | 1.07 ± 0.79             | 0.98 ± 0.78           |
| Total number of episode       | 8.5 ± 6.2           | 8.1 ± 6.1              | 11.0 ± 7.0              | 7.0 ± 5.6             |
| Number of mood stabilizers    | 1.4 ± 0.55          | 1.5 ± 0.58             | 1.8 ± 0.70              | 1.4 ± 0.58            |
| Number of antidepressants     | 0.45 ± 0.65         | 0.46 ± 0.66            | 0.46 ± 0.74             | 0.46 ± 0.69           |
| Number of antipsychotics      | 0.61 ± 0.70         | 0.67 ± 0.74            | 0.76 ± 0.77             | 0.71 ± 0.69           |
| Number of anxiolytics         | 0.39 ± 0.57         | 0.39 ± 0.56            | 0.42 ± 0.58             | 0.42 ± 0.60           |
| Number of hypnotics           | 0.85 ± 0.82         | 0.84 ± 0.80            | 0.99 ± 0.85             | 0.89 ± 0.87           |
| Daily dosage (mg/day)         | 559 ± 245           | 519 ± 270              | 363 ± 197               | 159 ± 100             |
| Range (mg/day)                | 25−1,500            | 100−1,600              | 50−1,000                | 5−600                 |
| Co-administered dosage (mg)   | -                   | 579 ± 249, n = 266     | 616 ± 253, n = 61       | 649 ± 260, n = 198    |
| Lithium                       | -                   | 538 ± 267, n = 266     | 677 ± 273, n = 31       | 552 ± 285, n = 77     |
| Valproic acid                 | 406 ± 192, n = 61   | 340 ± 183, n = 31      | 268 ± 194, n = 19       | -                     |
| Carbamazepine                 | 177 ± 103, n = 198  | 111 ± 68, n = 77       | 234 ± 119, n = 19       | -                     |

Values are presented as mean ± standard deviation.

1Junior high school graduate = 1, high school = 2, junior college = 3, college = 4, postgraduate degree = 5.
2Presence = 1, absent = 0.
3Global assessment of functioning (GAF) (81−100) = 0, GAF (61−80) = 1, GAF (41−60) = 2, GAF (< 41) = 3.

Statistical Analysis

The factors associated with the dose of mood stabilizers among bipolar disorder patients were examined using linear regression with forced entry. These factors included sex, height, weight, educational level, GAF score, psychiatric comorbidity, rapid cycle status, substance abuse, mood status, and total number of episodes. The dummy variables included were as follows: male = 1 and female = 2; junior high school graduate = 1, high school = 2, junior college = 3, college = 4, and postgraduate degree = 5; GAF (81−100) = 0, GAF (61−80) = 1, GAF (41−60) = 2, and GAF (< 41) = 3; depression = 1 and without depression = 0; mania = 1 and without mania = 0; psychotic feature = 1 and without psychotic feature = 0; suicidal ideation = 1 and without suicidal ideation = 0; rapid cycle = 1 and not rapid cycle = 0; and substance abuse = 1 and without substance abuse = 0. Pearson correlations were performed for association between doses of mood stabilizers. All statistical tests were based on a two-sided significance level of 0.05. The SPSS Statistics software program for Windows, version 25.0 (IBM Japan, Tokyo, Japan), was used for all analyses.

RESULTS

Completed questionnaires on 3,213 outpatients with bipolar disorder were returned from 176 originally solicited outpatient facilities. The characteristics of the subjects are shown in Table 1. Most patients received mood stabilizers such as lithium (n = 1,317), VPA (n = 808), CBZ (n = 136), and LTG (n = 665). The dose of LTG in patients receiving VPA was significantly lower than that in patients receiving lithium and CBZ.

The dose of lithium was directly correlated with body weight and number of episodes, and GAF and was inversely correlated with age and depression (Table 2). The dose of VPA was correlated with body weight, number of episodes, presence of a rapid cycle and GAF (Table 2). The dose of CBZ was correlated with mania and was inversely correlated with age and the presence of a rapid cy-
Table 2. Partial correlation coefficients of dose of mood stabilizers prescribed in the outpatients clinics using multiple regression analysis

| Variable                              | Lithium (n = 1,317) | Valproic acid (n = 809) | Carbamazepine (n = 136) | Lamotrigine (n = 665) |
|---------------------------------------|---------------------|-------------------------|-------------------------|-----------------------|
| Age                                   | -0.186***           | -0.038                  | -0.206*                 | -0.003                |
| Sex (male = 1, female = 2)            | -0.047              | 0.004                   | 0.076                   | 0.042                 |
| Height                                | 0.077               | -0.017                  | 0.163                   | 0.062                 |
| Weight                                | 0.115**             | 0.103*                  | -0.125                  | -0.003                |
| Education periods*                    | 0.045               | 0.055                   | 0.193                   | 0.007                 |
| Number of episode                     | 0.073**             | 0.116**                 | 0.049                   | 0.084*                |
| Presence of depressionb               | -0.070*             | -0.057                  | 0.017                   | -0.113*               |
| Presence of maniab                    | 0.021               | 0.042                   | 0.237**                 | -0.082*               |
| Presence of psychotic featuresb       | 0.012               | -0.018                  | 0.095                   | 0.089*                |
| Presence of suicidal ideationb        | -0.031              | 0.026                   | -0.047                  | 0.015                 |
| Presence of substance useb            | -0.032              | -0.015                  | -0.139                  | -0.005                |
| Presence of rapid cyclerb             | 0.019               | 0.090**                 | -0.203*                 | 0.101*                |
| Global assessment of functioningc     | 0.108**             | 0.072*                  | -0.011                  | 0.061                 |
| R                                     | 0.328***            | 0.213***                | 0.450**                 | 0.194*                |

R, multiple correlation coefficients.
*Junior high school graduate = 1, high school = 2, junior college = 3, college = 4, postgraduate degree = 5. **Presence = 1, absent = 0. **Global assessment of functioning (GAF) (81 - 100) = 0, GAF (61 - 80) = 1, GAF (41 - 60) = 2, GAF (< 41) = 3.

Table 3. Correlations between doses of mood stabilizers co-administered

| Drugs         | Lithium (n = 1,317) | Valproic acid (n = 808) | Carbamazepine (n = 136) | Lamotrigine (n = 665) |
|---------------|---------------------|-------------------------|-------------------------|-----------------------|
| Valproic acid | 0.254*** (n = 266)  |                         |                         |                       |
| Carbamazepine | 0.346** (n = 61)    | 0.454** (n = 31)        |                         |                       |
| Lamotrigine   | 0.139* (n = 198)    | -0.038 (n = 77)         | 0.557** (n = 19)        |                       |

*p < 0.05, **p < 0.01, ***p < 0.001.

cle (Table 2). The dose of LTG was correlated with the number of episodes, psychotic features, and the presence of a rapid cycle and was inversely correlated with the presence of depression and mania (Table 2).

The doses of coadministered mood stabilizers were significantly correlated with the combination of VPA and LTG (Table 3).

**DISCUSSION**

Mood stabilizers such as lithium and anticonvulsants are still standard-of-care for the acute and long-term treatment of bipolar disorder. The results of this study showed that age, body weight, number of episodes, presence of current mood disorders, presence of rapid cycle and social adjustment are associated with the doses of mood stabilizers, and this is the first report regarding mood stabilizer dosing and its related factors in the world.

We found a significant inverse correlation between daily doses of lithium and CBZ and age. These findings are reasonable because lithium is excreted by the kidneys [12], and renal function decreases with age [13]. In addition, CBZ is metabolized by liver enzymes, particularly CYP3A4 [12], whose activity decreases with age [14]. Therefore, serum concentrations of lithium and CBZ tend to increase with age. On the other hand, VPA and LTG are metabolized by glucuronic acid conjugation, which, unlike compared with CYPs, is not influenced by age.

Depression decreased the doses of lithium and LTG in the study. The recommended doses of lithium were 600 - 1,200 mg/day during the manic episode and 600 - 1,800 mg/day during the depressive episode [3], suggesting that the daily dose of lithium during the depressive episode should be higher than that during the manic episode. However, our findings demonstrated a lower dose of lithium in patients with depression, although the average daily dose of lithium was approximately 560 mg/day, which is low compared with the world standard recommended dose [3]. We do not have a clear explanation for this discrepancy. The recommended doses of LTG were 50 - 200 mg/day during depressive episodes and 50 - 400 mg/day during maintenance episodes [3], suggesting that
the daily dose of LTG during depressive episodes should be lower than that during maintenance episodes. Our results for LTG were in line with the guidelines [3].

The number of episodes was correlated with the doses of lithium and VPA in the study. Although the recommended doses for these mood stabilizers were not shown in the guidelines, lithium and VPA were consistently ranked as the 1st line treatments [3-5]. Therefore, lithium and VPA might be regarded as the main agents for the prevention of repeated episodes.

The presence of rapid cycling was directly correlated with the doses of VPA and LTG and inversely correlated with the dose of CBZ. CINP guidelines say that aripiprazole, quetiapine and VPA were the first-line treatments for rapid-cycling patients, and olanzapine and lithium were recommended as second-line strategies [15], but LTG was not different from placebo in the context of maintenance treatment in patients with rapid cycling [16]. On the other hand, a combination of LTG and mood stabilizers (or atypical antipsychotics) was potentially preferable during episodes of current depression according to KMAP-BP 2018 [5].

Patients who have better response to lithium are a group of patients with bipolar disorder core phenotype clinical features [17,18]. An non-episodic pattern of the mania-depression interval, high rates of comorbid conditions, rapid cycling and younger age at illness onset have been identified as potentially risk against recurrence during the lithium treatment [19-22]. Patients who have better response to VPA are characterized by the presence of pure, mixed or dysphoric mania. In addition, elder age at onset, absence of rapid cycling, absence of concurrent substance abuse and lack of response or intolerance to lithium are clinical predictors of positive outcome of treatment with VPA [23]. Patients who have better response to CBZ seems to be predicted by clinical features such as mood-incongruent psychosis and lack of response or intolerance to lithium are clinical predictors of presence of rapid cycling, severe mania and dysphoric mania [24,25]. Earlier onset of symptoms, nonepisodic course of illness, rapid cycling, comorbidity with a panic or substance use disorder, fewer hospitalizations, fewer prior medication trials and male sex may be predictors in patients who have better response to LTG [26,27].

This study has several notable limitations. First, this was a cross-sectional study, so we could not determine causal relationships. The second limitation of this study was the lack of a structural clinical evaluation of patients, although clinical evaluation in this study was performed by doctors in charge of the patients who were well trained. Additionally, selection bias may have occurred because the subjects were not randomized. Finally, there may be problems with population heterogeneity because we did not distinguish between bipolar I and II. Thus, some interrater variability cannot be excluded. Further longitudinal studies are needed to confirm the detailed prescription patterns for patients with bipolar disorder in Japan.

Acknowledgments

This study was supported by Ken Tanaka memorial research grant.

The authors thank the following psychiatrists belonging to the Japanese Association of Neuro-Psychiatric Clinics: Dr. Toshihiko Lee, Dr. Norio Okamoto, Dr. Makoto Nakamura, Dr. Junkou Sato, Dr. Kazunori Otaka, Dr. Satoshi Terada, Dr. Tadashi Ito, Dr. Munehide Tani, Dr. Atsushi Satomura, Dr. Satoshi Tsuchiya, Dr. Hiroshi Sato, Dr. Hideki Nakano, Dr. Yoichi Nakaniwa, Dr. Eiichi Hirayama, Dr. Keiichi Kobatake, Dr. Koji Tanaka, Dr. Mariko Watanabe, Dr. Shiguyuki Uehata, Dr. Asana Yuki, Dr. Nobuko Akagaki, Dr. Michie Sakano, Dr. Akira Matsukubo, Dr. Yukihisa Kibota, Dr. Yasuyuki Inada, Dr. Hiroshi Oyu, Dr. Tsuneo Tsubaki, Dr. Tatsuyi Tamura, Dr. Shigeki Akiu, Dr. Atsuo Kikuchi, Dr. Keiji Sato, Dr. Kazuyuki Fujita, Dr. Fumio Handa, Dr. Hiroyuki Karasawa, Dr. Kazuhiro Nakano, Dr. Kazuhiro Omori, Dr. Seiji Tagawa, Dr. Daiisuke Maruno, Dr. Hiroaki Furui, Dr. You Suzuki, Dr. Takeshi Fujita, Dr. Yukimitsu Hoshino, Dr. Kikuko Ota, Dr. Akira Itami, Dr. Kenichi Goto, Dr. Yoshiaki Yamano, Dr. Kichiro Koshimune, Dr. Junko Matsushita, Dr. Takatsugu Nakayama, Dr. Kazuyoshi Takamuki, Dr. Nobumichi Sakamoto, Dr. Miho Shimizu, Dr. Muneya Shimura, Dr. Norio Kawase, Dr. Ryouhei Takeda, Dr. Takuya Hirota, Dr. Hideko Fujii, Dr. Yoichiro Watanabe, Dr. Riichiro Narabayashi, Dr. Yutaka Fujiwara, Dr. Kazu Kobayashi, Dr. Yoko Urabe, Dr. Miyako Ogura, Dr. Osamu Miura, Dr. Yoshio Ikeda, Dr. Hidemi Sakamoto, Dr. Yosuke Yonezawa, Dr. Yoichi Takei, Dr. Toshimasa Sakane, Dr. Kiyoshi Oka, Dr. Kyoko Tsuda, Dr. Shigemitsu Hayashi, Dr. Kunihiko Kawamura, Dr. Yasushi Furuta, Dr. Kazuko Miyauchi, Dr. Yoshio Miyauchi, Dr. Mikako
Dr. Yasui-Furukori has received grant/research support or honoraria from and been on the speakers of Dainippon Sumitomo Pharma, Astellas Pharma, Meiji Seika Pharma, Eisai, Pfizer, Otsuka Pharmaceutical, Daiichi Sankyo, and Takeda Pharmaceutical, and honoraria from Eisai, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical, Meiji Seika Pharma, Janssen Pharmaceutical, Shionogi, Dainippon Sumitomo Pharma, Daiichi Sankyo, and Pfizer. Dr. Yoshimura has received speaker’s honoraria from Eli Lilly, Janssen, Dainippon Sumitomo, Otsuka, Meiji, Pfizer and Shionogi. Dr. Kato has received grant funding from Japan Society for the Promotion of Science, SENSIN Medical Research Foundation and Japan Research Foundation for Clinical Pharmacology, and speaker’s honoraria from Dainippon-Sumitomo Pharma, Otsuka, Meiji-Seika Pharma, Eli Lilly, MSD K.K., GlaxoSmithKline, Pfizer, Janssen Pharmaceutical, Shionogi, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical and Ono Pharmaceutical.

Dr. Azekawa has received speaker’s honoraria from Eli Lilly, Otsuka Pharmaceutical, and Pfizer. Dr. Ueda has received manuscript fees or speaker’s honoraria from Eli Lilly, Otsuka Pharmaceutical, and Pfizer. Dr. Edagawa has received speaker’s honoraria from Eli Lilly, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, MSD, Otsuka Pharmaceutical, Pfizer, Sumitomo Dainippon Pharma, Takeda Pharmaceutical, and Yoshitomi Yakuhin. Dr. Edagawa has received speaker’s honoraria from Eli Lilly, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, MSD, Otsuka Pharmaceutical, Pfizer, Sumitomo Dainippon Pharma, Takeda Pharmaceutical, and Yoshitomi Yakuhin. Dr. Edagawa has received speaker’s honoraria from Eli Lilly, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, MSD, Otsuka Pharmaceutical, Pfizer, Sumitomo Dainippon Pharma, Takeda Pharmaceutical, and Yoshitomi Yakuhin.

Dr. Kubota has received consultant fees from Pfizer and Meiji-Seika Pharma and speaker’s honoraria from Meiji-Seika Pharma, Eli Lilly, Janssen Pharmaceutical, Dainippon Sumitomo Pharma, Mitsubishi Tanabe Pharma, Otsuka Pharmaceutical, and Eisai. Dr. Goto has received manuscript fees or speaker’s honoraria from Eli Lilly, Janssen Pharmaceutical, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, MSD, Otsuka Pharmaceutical, Pfizer, Sumitomo Dainippon Pharma, Kyowa and Yoshitomi Yakuhin. Dr. Katsumoto has received speaker’s honoraria from Daiichi Sankyo, Sankyo, Eli Lilly, Janssen Pharmaceutical, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, MSD, Otsuka Pharmaceutical, Pfizer, Sumitomo Dainippon Pharma, Takeda Pharmaceutical, and Yoshitomi Yakuhin.

Dr. Hongo has received manuscript fees or speaker’s honoraria from Eli Lilly, Janssen Pharmaceutical, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, MSD, Otsuka Pharmaceutical, Pfizer, Sumitomo Dainippon Pharma, UCB. Dr. Kubota has received consultant fees from Pfizer and Meiji-Seika Pharma and speaker’s honoraria from Meiji-Seika Pharma, Eli Lilly, Janssen Pharmaceutical, Dainippon Sumitomo Pharma, Mitsubishi Tanabe Pharma, Otsuka Pharmaceutical, and Eisai. Dr. Goto has received manuscript fees or speaker’s honoraria from Eli Lilly, Janssen Pharmaceutical, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, MSD, Otsuka Pharmaceutical, Pfizer, Sumitomo Dainippon Pharma, and Yoshitomi Yakuhin.

Dr. Tsuboi has received consultant fees from Pfizer and

**Conflicts of Interest**

Dr. Yasui-Furukori has received grant/research support or honoraria from and been on the speakers of Dainippon Sumitomo Pharma, Mochida Pharmaceutical, MSD, and Otsuka Pharmaceutical. Dr. Shimoda has received research support from Novartis Pharma, Dainippon Sumitomo Pharma, Astellas Pharma, Meiji Seika Pharma, Eisai, Pfizer, Otsuka Pharmaceutical, Daiichi Sankyo, and Takeda Pharmaceutical, and honoraria from Eisai, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical, Meiji Seika Pharma, Janssen Pharmaceutical, Shionogi, Dainippon Sumitomo Pharma, Daiichi Sankyo, and Pfizer. Dr. Yoshimura has received speaker’s honoraria from Eli Lilly, Janssen, Dainippon Sumitomo, Otsuka, Meiji, Pfizer and Shionogi. Dr. Kato has received grant funding from Japan Society for the Promotion of Science, SENSIN Medical Research Foundation and Japan Research Foundation for Clinical Pharmacology, and speaker’s honoraria from Dainippon-Sumitomo Pharma, Otsuka, Meiji-Seika Pharma, Eli Lilly, MSD K.K., GlaxoSmithKline, Pfizer, Janssen Pharmaceutical, Shionogi, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical and Ono Pharmaceutical.
speaker’s honoraria from Eli Lilly, Meiji-Seika Pharma, MSD, Janssen Pharmaceutical, Dainippon Sumitomo Pharma, Mitsubishi Tanabe Pharma, Yoshitomi Yakuhin, Mochida Pharmaceutical, Otsuka Pharmaceutical, Kyowa Pharmaceutical, and Takeda Pharmaceutical. Dr. Nakagawa has received lecture fees from Pfizer, Eli Lilly, Otsuka, Janssen Pharmaceutical, Mitsubishi Tanabe, Mochida, Dainippon Sumitomo and NTT Doconmo, and participated in an advisory board for Takeda, Meiji Seika and Tsumura. Dr. Kikuchi has received consultant fees from Takeda Pharmaceutical and Center for Cognitive Behavioral Therapy and Training. Dr. Watanabe has received manuscript fees or speaker’s honoraria from Daiichi Sankyo, Eisai, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceutical, Kyowa Pharmaceutical, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, MSD, Otsuka Pharmaceutical, Pfizer, Shionogi, Sumitomo Dainippon Pharma, Takeda Pharmaceutical, Yoshitomi Yakuhin, and has received research/grant support from Astellas Pharma, Daiichi Sankyo, Eisai, MSD, Mitsubishi Tanabe Pharma, Meiji Seika Pharma, Otsuka Pharmaceutical, Pfizer, Shionogi, Sumitomo Dainippon Pharma, and is a consultant of Eisai, Eli Lilly, Kyowa Pharmaceutical, Otsuka Pharmaceutical, Pfizer, Sumitomo Dainippon Pharma, Taisho Toyama Pharmaceutical, and Takeda Pharmaceutical.

Author Contributions

Conceptualization: Norio Yasui-Furukori and Koichiro Watanabe. Data acquisition: Naoto Adachi, Yukihsa Kubota, Takaharu Azekawa, Eiichiro Goto, Koji Edagawa, Eiichi Katsumoto, Seiji Hongo, Hitoshi Ueda, and Kazuhira Miki. Formal analysis: Naoto Adachi. Funding: Koichiro Watanabe. Supervision: Masaki Kato, Reiji Yoshimura, Atsuo Nakagawa, Toshiaki Kikuchi, Takashi Tsuboi, and Koichiro Watanabe. Writing—original draft: Norio Yasui-Furukori. Writing—review & editing: Norio Yasui-Furukori and Kazutaka Shimoda.

ORCID

Norio Yasui-Furukori https://orcid.org/0000-0002-4414-3770
Naoto Adachi https://orcid.org/0000-0001-8376-4900
Yukihsa Kubota https://orcid.org/0000-0002-9837-6799
Takaharu Azekawa https://orcid.org/0000-0003-4294-4600
Eiichiro Goto https://orcid.org/0000-0001-8087-4549
Koji Edagawa https://orcid.org/0000-0003-1970-0042
Eiichi Katsumoto https://orcid.org/0000-0001-9417-4391
Seiji Hongo https://orcid.org/0000-0002-5997-8906
Hitoshi Ueda https://orcid.org/0000-0001-8950-2872
Kazuhira Miki https://orcid.org/0000-0003-3056-8038
Masaki Kato https://orcid.org/0000-0001-6727-7272
Reiji Yoshimura https://orcid.org/0000-0002-7637-5576
Atsuo Nakagawa https://orcid.org/0000-0002-2294-2571
Toshiaki Kikuchi https://orcid.org/0000-0003-1025-8796
Takashi Tsuboi https://orcid.org/0000-0002-8253-8888
Koichiro Watanabe https://orcid.org/0000-0002-0736-7070
Kazutaka Shimoda https://orcid.org/0000-0002-9663-6243

REFERENCES

1. Parker GB, Graham RK, Tavella G. Is there consensus across international evidence-based guidelines for the management of bipolar disorder? Acta Psychiatr Scand 2017;135:515-526.
2. Miura T, Noma H, Furukawa TA, Mitsuyasu H, Tanaka S, Stockton S, et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry 2014;1:351-359.
3. Fountoulakis KN, Grunze H, Vieta E, Young A, Yatham L, Blier P, et al. The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for bipolar disorder in adults (CINP-BD-2017), part 3: the clinical guidelines. Int J Neuropsychopharmacol 2017;20:180-195.
4. Yatham LN, Kennedy SH, Panikh SV, Schaffer A, Bond DJ, Frey BN, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 2018;20:97-170.
5. Woon YS, Bahk WM, Lee JG, Jeong JH, Kim MD, Sohn I, et al. Korean Medication Algorithm Project for Bipolar Disorder 2018 (KMAP-BP 2018): fourth revision. Clin Psychopharmacol Neurosci 2018;16:434-448.
6. Hiemke C, Bergemann N, Clément HW, Conca A, Deckert J, Domschke K, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry 2018;51:e1.
7. Steen NE, Aas M, Simonsen C, Dieset I, Tesli M, Nerhus M, et al. Serum concentrations of mood stabilizers are associated with memory, but not other cognitive domains in psychosis spectrum disorders; explorative analyses in a naturalistic setting. Int J Bipolar Disord 2016;4:24.
8. Pharmaceuticals and Medical Devices Agency. Regarding compliance with blood concentration measurement during administration of lithium carbonate; request of the pharmaceutical products proper use from Pharmaceuticals and Medical Devices Agency (PMDA) [Internet]. Tokyo: Pharmaceuticals and Medical Devices Agency; 2012 Sep [cited at 2020 May 1]. Available from: https://www.pmda.go.jp/files/000145551.
9. Murru A, Popovic D, Pacchiaroti I, Hidalgo D, León-Caballero J, Vieta E. Management of adverse effects of mood stabilizers. Curr Psychiatry Rep 2015;17:603.

10. Adachi N, Kubota Y, Goto E, Ueda H, Azekawa T, Hongo S, et al. [Estimated population with affective disorders in membership clinics of the Japanese Association of Neuropsychiatric Clinics]. J Jpn Assoc Psychiatr Clin 2016;42:957-959. Japanese.

11. Tsuboi T, Suzuki T, Azekawa T, Adachi N, Ueda H, Endagawa K, et al. Factors associated with non-remission in bipolar disorder: the multicenter treatment survey for bipolar disorder in psychiatric outpatient clinics (MUSUBI). Neuropsychiatr Dis Treat 2020;16:881-890.

12. Wang PW, Ketter TA. Pharmacokinetics of mood stabilizers and new anticonvulsants. Psychopharmacol Bull 2002;36:44-66.

13. Williams L, Lowenthal DT. Drug therapy in the elderly. South Med J 1992;85:127-131.

14. Greenblatt DJ, Harmatz JS, Shapiro L, Engelhardt N, Gouthero TA, Shader RL. Sensitivity to triazolam in the elderly. N Engl J Med 1991;324:1691-1698.

15. Fountoulakis KN, Kontis D, Gonda X, Yatham LN. A systematic review of the evidence on the treatment of rapid cycling bipolar disorder. Bipolar Dis 2013;15:115-137.

16. Calabrese JR, Suppes T, Bowden CL, Sachs GS, Swann AC, McElroy SL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 2000;61:841-850.

17. Baldessarini RJ, Tondo L. Does lithium treatment still work? Evidence of stable responses over three decades. Arch Gen Psychiatry 2000;57:187-190.

18. Soares JC, Cersosim S. The psychopharmacologic specificity of the lithium ion: origins and trajectory. J Clin Psychiatry 2000;61 Suppl 9:16-22.

19. Grof P, Alda M, Grof E, Fox D, Cameron P. The challenge of predicting response to stabilising lithium treatment. The importance of patient selection. Br J Psychiatry Suppl 1993;(21):16-19.

20. Calabrese JR, Fatemi SH, Kujawa M, Woyshville MJ. Predictors of response to mood stabilizers. J Clin Psychopharmacol 1996;16(2 Suppl 1):245-315.

21. Bowden CL. Clinical correlates of therapeutic response in bipolar disorder. J Affect Disord 2001;67:257-265.

22. Kleinderst N, Engel R, Greil W. Which clinical factors predict response to prophylactic lithium? A systematic review for bipolar disorders. Bipolar Disord 2005;7:404-417.

23. Ketter TA, Wang PW. Predictors of treatment response in bipolar disorders: evidence from clinical and brain imaging studies. J Clin Psychiatry 2002;63 Suppl 3:21-25.

24. Alda M. The phenotypic spectra of bipolar disorder. Eur Neuropsychopharmacol 2004;14 Suppl 2:S94-S99.

25. De León OA. Antiepileptic drugs for the acute and maintenance treatment of bipolar disorder. Harv Rev Psychiatry 2001;9:209-222.

26. Obrocea GV, Dunn RM, Frye MA, Ketter TA, Luckenbaugh DA, Leverich GS, et al. Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biol Psychiatry 2002;51:253-260.

27. Passmore MJ, Gannam J, Duffy A, MacDougall M, Munro A, Slaney C, et al. Phenotypic spectra of bipolar disorder in responders to lithium versus lamotrigine. Bipolar Disord 2003;5:110-114.